ProteoTech

About:

ProteoTech is a drug development company that offers therapeutics and diagnostics for amyloid diseases.

Description:

ProteoTech, Inc., also known as Proteoglycan Technologies, Inc., operates as a drug development company in the United States. The company offers therapeutics and diagnostics for amyloid diseases. Its products include Exebryl-1, a molecule compound to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques found in Alzheimer's brains of disease victims; PeptiClere, a nasal spray for the treatment of Alzheimer's disease; Synuclere for the treatment of Parkinson's disease; and Systebryl, a small molecule compound for the treatment of systemic amyloidosis associated with type 2 diabetes. ProteoTech, Inc. was founded in 1996 and is headquartered in Kirkland, Washington.

Total Funding Amount:

$10.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kirkland, Washington, United States

Founded Date:

1996-01-01

Contact Email:

info(AT)proteotech.com

Founders:

Alan Snow

Number of Employees:

1-10

Last Funding Date:

2011-06-28

IPO Status:

Private

Industries: